Akash Tewari
Stock Analyst at Wolfe Research
(1.92)
# 2,980
Out of 4,670 analysts
58
Total ratings
32.56%
Success rate
-4.06%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $64.26 | +47.84% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $113.13 | +32.59% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $4.75 | +236.84% | 3 | Sep 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $49 → $51 | $58.87 | -13.37% | 2 | Aug 28, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $125.65 | +50.42% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $30.77 | +159.99% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $34.01 | +120.52% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $994 → $1,015 | $748.01 | +35.69% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $28.78 | +73.73% | 6 | Apr 9, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $37 → $75 | $43.46 | +72.57% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $27.70 | +11.91% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $32 → $40 | $25.86 | +54.68% | 2 | Dec 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $738.00 | +26.96% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $4.70 | +155.32% | 2 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.65 | +52.05% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $9.34 | +92.72% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $605.92 | -15.34% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.79 | +210.88% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $99.18 | +26.03% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $14.29 | -23.02% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $12.47 | -71.13% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $6.55 | +159.54% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $49.10 | +52.75% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $347.45 | -56.54% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $35.61 | -21.37% | 3 | Oct 7, 2021 |
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $64.26
Upside: +47.84%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $113.13
Upside: +32.59%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $4.75
Upside: +236.84%
Bristol-Myers Squibb Company
Aug 28, 2024
Maintains: Hold
Price Target: $49 → $51
Current: $58.87
Upside: -13.37%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $125.65
Upside: +50.42%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $30.77
Upside: +159.99%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $34.01
Upside: +120.52%
Eli Lilly
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $748.01
Upside: +35.69%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $28.78
Upside: +73.73%
Apogee Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $43.46
Upside: +72.57%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $27.70
Upside: +11.91%
Dec 6, 2023
Upgrades: Buy
Price Target: $32 → $40
Current: $25.86
Upside: +54.68%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $738.00
Upside: +26.96%
Nov 28, 2023
Maintains: Buy
Price Target: $15 → $12
Current: $4.70
Upside: +155.32%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.65
Upside: +52.05%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $9.34
Upside: +92.72%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $605.92
Upside: -15.34%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $5.79
Upside: +210.88%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $99.18
Upside: +26.03%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $14.29
Upside: -23.02%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $12.47
Upside: -71.13%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $6.55
Upside: +159.54%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $49.10
Upside: +52.75%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $347.45
Upside: -56.54%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $35.61
Upside: -21.37%